Alzheimer’s Initiative Widens Research Focus on Frontotemporal Degeneration With New $5M Commitment

Alzheimer’s Initiative Widens Research Focus on Frontotemporal Degeneration With New $5M Commitment
With a new $5-million commitment, the Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator initiative is expanding its focus on frontotemporal degeneration, the most common form of dementia for individuals under 60. The funds come from a new research pledge of $2.5 million from The Association for Frontotemporal Degeneration (AFTD), which is being matched by a $2.5-million allocation of funds from the ADDF's Diagnostics Accelerator initiative, which was launched last summer as a venture philanthropy vehicle with seed money from philanthropist Bill Gates, among others. The program is part of a three-year, $35-million plan to develop new biomarkers for diseases such as Alzheimer’s and FTD, a group of disorders caused by progressive nerve cell loss in the brain’s frontal or temporal lobes. Biomarkers can be used to predict the likelihood an individual will develop a disease, more easily identify patients for clinical trials, and more accurately monitor response to treatments. Current tests for Alzheimer’s are pricey and invasive. “Early and accurate diagnosis is the key to any research gains for those who suffer from dementia,” Susan L-J Dickinson, AFTD's chief executive officer, said in a
Subscribe or to access all post and page content.